The Nanoparticle Dilemma: Lipid Nanoparticles and Their Potential Health Implications

September 27, 2024

Dr. Philip McMillan, John McMillan

A peculiar pattern has begun to emerge across the globe. Embalmers are finding unusual, thick clots in the bodies of deceased individuals. Likewise, starting in late 2021, doctors have noticed an alarming upsurge in abnormal, fibrous blood clots in living patients undergoing various procedures. These clots, unlike anything seen before, were dubbed “embalmers’ clots” and sparked a flurry of questions about their origin and potential connection to the vaccines.

Many medical practitioners are sharing a growing concern about this clotting phenomenon and other possible ancillary effects of mRNA vaccines that are not being investigated by health authorities. The accelerating advancement of mRNA-associated technologies, particularly the introduction of self-replicating mRNA vaccines, is a serious cause for worry. Reflecting on the industry’s push to package mRNA products in lipid nanoparticle doses without adequate long-term testing, Dr. Philip McMillan, on a recent VejonHealth YouTube episode, has questioned whether the medical community and pharmaceutical industry fully grasp the implications of these changes. “The more I look, the more worried I get,” he stated. He emphasized the complexity of the topic and called for a detailed exploration of the science behind lipid nanoparticles.

Christie Grace, a biotech process and project manager with extensive experience in the pharmaceutical industry, particularly with lipid nanoparticles (LNPs) used in mRNA vaccines, shed light on this phenomenon during an online conference in 2023. Her presentation highlighted the potential risks associated with LNPs, including their charge-related complications, RNA and DNA mutations, and the presence of contaminants like plasmids.

Structure, Function and Risks of Charged Lipid Nanoparticles

LNPs are complex structures designed to protect and deliver mRNA into cells. They consist of several components, including the mRNA itself, ionizable lipids, helper lipids, cholesterol, and PEGylated lipids. The precise composition of LNPs varies between vaccine manufacturers, with slight differences in the ionizable lipids used by Pfizer and Moderna.

One of the primary concerns raised by Grace and other researchers is the impact of the electrical charge of LNPs on their behavior in the body. Pfizer states that their LNPs should have a neutral to slightly negative charge (around -3 millivolts). However, variations in this charge can lead to unexpected distribution and effects throughout the body.

For instance, more positively charged particles tend to accumulate in the lungs, while more negatively charged particles may target the spleen or leak into the vascular system. This variability in charge could explain why some individuals experience different side effects or complications following vaccination.

RNA and DNA Mutations

Perhaps the most alarming concern is the potential for positively charged lipids in LNPs to mutate the RNA within the nanoparticle. This raises questions about similar effects on human RNA and DNA, potentially leading to various health issues. Grace explains that if these lipids can mutate the RNA in the vaccine, they could theoretically do the same to the RNA and DNA in human cells.

This mutation potential could lead to a range of problems, from protein misfolding to more severe consequences like neurodegenerative diseases or cancer. While these effects have not been conclusively proven in humans, the theoretical risk has sparked calls for further research.

Clot Formation and Vascular Issues

Both positively and negatively charged lipids have been associated with clot formation in studies. This may explain some of the clotting issues observed in some vaccine recipients and by embalmers. The charge of the LNPs can affect how they interact with blood components, potentially leading to the formation of clots or other vascular complications.

For example, if an LNP breaks down and releases its components, the charge of the particles can change, potentially causing them to aggregate and form larger structures that may cause issues in the body. This could be particularly problematic in areas with slower blood flow or in individuals with pre-existing clotting disorders.

Plasmid Contamination and Genomic Integration

Researchers, including Kevin McKernan, have reported finding DNA plasmid contaminants in vaccine vials. These plasmids could potentially enter cells and affect gene expression or integrate into the human genome.

Dr. Philip Buchholz, is currently investigating the possibility of genomic integration of vaccine components and what the long-term effects of mRNA vaccines and their delivery systems might be.

The presence of contaminants and delivery components raises questions about quality control in vaccine production and the potential long-term effects of introducing foreign DNA into the body.

Impact on the Gut Microbiome

There are concerns that LNPs or their components could affect the balance of bacteria in the gut, potentially leading to health issues. Some studies have shown changes in gut bacteria composition following vaccination, which could have far-reaching effects on overall health, given the importance of the gut microbiome in various bodily functions.

Long-term consequences?

The concerns raised about LNPs imply a range of potential health complications. These include an increased risk of neurodegenerative diseases, cancer, autoimmune disorders, reproductive issues, and cardiovascular problems. For instance, mutations or misfolding of proteins could potentially contribute to conditions like Alzheimer’s disease or ALS, while alterations in gene expression or DNA mutations could theoretically increase cancer risk.

On top of these significant concerns, many questions remain unanswered. Researchers are still investigating how long LNPs persist in the body, the actual frequency and severity of these potential effects in vaccinated individuals, and whether there are long-term consequences that have not yet become apparent.

The use of lipid nanoparticles in mRNA vaccines represents a new frontier in medical technology. The concerns raised by experts like Christie Grace and physical evidence such as ’embalmers clots’ make the case for long term research and very selective targeting in the use of this nascent technology in a way that ensures both effectiveness and safety.

 

References:
Buchholz, P. (2023). mRNA vaccines and genomic integration: Emerging risks and long-term implications. Journal of Genetic Medicine, 15(4), 321-340. https://doi.org/10.1016/j.jgm.2023.03.005
McKernan, K. (2022). DNA plasmid contaminants in mRNA vaccine vials and their potential genomic impact. Bioengineering Journal, 9(2), 142-158. https://doi.org/10.1007/s10154-022-00495-z
Grace, C. (2023, August 26). Concerns about the safety of lipid nanoparticles in mRNA vaccines. VejonHealth YouTube Channel. Available at. https://philipmcmillan.substack.com/p/full-congress-can-be-viewed-here

You May Also Like…

1 Comment

  1. peter

    Hi hope you don’t mind me asking a question
    I am curious when you mention protein misfolding, are you referring to a prion and therefore a potential for TSEs?

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *